Postpartum psychosis is a psychiatric emergency. Evidence supports early use of lithium plus antipsychotics—and, when needed, ECT—to achieve remission and prevent relapse.
An open-label pilot study suggests that intravenous brexanolone may rapidly reduce psychotic, manic, and depressive symptoms in patients with postpartum psychosis, highlighting a potential new treatment option.
Emerging data suggest that severe sleep loss around labor and delivery may mediate the link between bipolar disorder and postpartum psychosis, offering new targets for prevention.
Including postpartum psychosis in the DSM may help improve awareness, but it is only the first step in ensuring timely recognition and effective care.
The MGHP3 study provides key insights into the onset, duration, treatment, and characteristics of postpartum psychosis in a large, diverse cohort.
Loss of at least one night’s sleep at the time of labor and delivery is a potent risk factor for postpartum psychosis in women with bipolar disorder.
Postpartum psychosis is the most severe form of postpartum psychiatric illness. What are the signs and symptoms?
Dr. Lee S. Cohen, Director of the Ammon-Pinizzotto Center for Women's Mental Health at Massachusetts General Hospital, recently shared his insights on clinical issues regarding prescribing antidepressants during pregnancy with Ob.Gyn News on August 16, [...]
Women with postpartum psychosis are at risk for recurrent illness, but we have limited data regarding risk factors for recurrence.
Margaret Spinelli, MD will be presenting to the DSM-V committee of the American Psychiatric Association arguing for the inclusion of postpartum psychosis as a unique diagnosis.
